Open Access Open Access  Restricted Access Subscription or Fee Access

Therapeutic and Preventive Approaches against COVID-19: A Review

Ilyes Zatla, Lamia Boublenza, Hafida Hassaine


Several vaccines are found for the novel coronavirus SARS-CoV-2, responsible for the Coronavirus Disease ‘COVID-19’ but with a no clear, unified and effective treatment plan, nor definitive therapies for it, but only a variety of potential approaches. The objective of this work was to present, an overview of a variety of therapeutic and preventive approaches that have been applied instead, in a matter to calm the fatal viral pneumonia and developing safe, effective, anti-coronavirus therapeutic agents from naturally derived compounds would make a hopeful solution to end this pandemic. A number of experimental therapies have been rushed into clinical trials for COVID-19 patients, and with medical journals publishing new COVID-19 research studies at breakneck speed, it can be difficult to keep up with the latest news and guidelines. Potential anti-coronavirus therapies can be divided into two categories depending on the target, one acting on the human immune system or human cells, and another, on the virus itself.


SARS-CoV-2, COVID-19, mask, therapy, vaccine.

Full Text:



Akram, A. and Mannan, N., 2020. Molecular structure, pathogenesis and virology of SARS-CoV-2: A review. Bangladesh Journal of Infectious Diseases, pp.S36-S40.

Alanagreh, L.A., Alzoughool, F. and Atoum, M., 2020. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens, 9(5), p.331.

Lam, T.T.Y., Jia, N., Zhang, Y.W., Shum, M.H.H., Jiang, J.F., Zhu, H.C., Tong, Y.G., Shi, Y.X., Ni, X.B., Liao, Y.S. and Li, W.J., 2020. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature, 583(7815), pp.282-285.

Romano, M., Ruggiero, A., Squeglia, F., Maga, G. and Berisio, R., 2020. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells, 9(5), p.1267.

Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., Duan, Y., Zhang, H., Wang, Y., Qian, Z. and Cui, J., 2020. On the origin and continuing evolution of SARS-CoV-2. National Science Review, 7(6), pp.1012-1023.

Bhowmik, D., Pal, S., Lahiri, A., Talukdar, A. and Paul, S., 2020. Emergence of multiple variants of SARS-CoV-2 with signature structural changes. BioRxiv.

De Soto J, Hakim S, Boyd F. The Pathophysiology of Virulence of the COVID-19. Preprints. 2020; 2020040077.

Van Doremalen, N., Bushmaker, T., Morris, D.H., Holbrook, M.G., Gamble, A., Williamson, B.N., Tamin, A., Harcourt, J.L., Thornburg, N.J., Gerber, S.I. and Lloyd-Smith, J.O., 2020. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England journal of medicine, 382(16), pp.1564-1567.

Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020; 5(4): 536–44p.

Gu, J., Han, B. and Wang, J., 2020. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology, 158(6), pp.1518-1519.

Haque, M.A. and Akram, L., 2020. Different management strategy of Covid19 patients. Bangladesh Journal of Infectious Diseases, pp.S51-S53.

Jogalekar MP, Veerabathini A, Gangadaran P. Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions. Experimental Biology and Medicine. 2020; 1–6p.

Valencia, D.N., 2020. Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2. Cureus, 12(3).

Howard, J., Huang, A., Li, Z., Tufekci, Z., Zdimal, V., van der Westhuizen, H.M., von Delft, A., Price, A., Fridman, L., Tang, L.H. and Tang, V., 2021. An evidence review of face masks against COVID-19. Proceedings of the National Academy of Sciences, 118(4).

Feng, S., Shen, C., Xia, N., Song, W., Fan, M. and Cowling, B.J., 2020. Rational use of face masks in the COVID-19 pandemic. The Lancet Respiratory Medicine, 8(5), pp.434-436.

Morawska, L. and Cao, J., 2020. Airborne transmission of SARS-CoV-2: The world should face the reality. Environment international, 139, p.105730.

Lai C-C, Shih T-P, Ko W-C, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. 2020; 55(3): 105924p.

Chiu W-T, Laporte RP, Wu J. Determinants of Taiwan’s Early Containment of COVID-19 Incidence. Am. J. Public Health. 2020; 110(7): 943–4p.

Saeed MA, Zaher TI, Khorshed SE, et al. The SARS-COV2 (COVID-19) Pandemic: What Clinicians should knew. Afro-Egyptian Journal of Infectious and Endemic Diseases. 2020; 10(2): 61–4p.

Yi Y, Lagniton PNP, Ye S, et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Intel. J. Biol. Sci. 2020; 16(10): 1753–66p.

Petrosillo N. SARS-CoV-2, “common cold” coronaviruses’ cross-reactivity and “herd immunity”: The razor of Ockham (1285-1347)? Infect. Dis. Rep. 2020; 12(2): 8647p.

Mani JS, Johnson JB, Steel JC, et al. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res. 2020; 284: 197989p.

Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020; 395(10235): 1517–20p.

Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485): 1444–8p.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–80p.

Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021; 28(9): 740–6p.

Ulrich H, Pillat MM. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev. 2020; 16(3): 434–40p.

Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 2020; 178: 104787p.

Abrahams L. Covid-19: acquired acute porphyria hypothesis. OSF Preprint. 2020.

Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229): 1033–4p.

Vellingiri B, Jayaramayya K, Iyer M, et al. COVID-19: A promising cure for the global panic. Sci. Total Environ. 2020; 725: 138277p.

Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020; 20(4): 400–2p.

Anastasopoulou S, Mouzaki A. The biology of SARS-CoV-2 and the ensuing COVID-19. Achaiki Iatriki. 2020; 39(1): 29–35p.

Patel JC, Tulswani R, Khurana P, et al. Identification of pulmonary comorbid diseases network based repurposing effective drugs for COVID-19. Research Square [Preprint]. 2020.

Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. 2020; 117(20): 10970–5p.

Yaqinuddin A, Kashir J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. Med. Hypotheses. 2020; 140: 109777p.

Dong J, Huang B, Jia Z, et al. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. Emerg. Microbes Infect. 2020; 9(1): 1034–6p.

Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit. Care. 2020; 24(1).

Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J. Clin. Investig. 2020; 130(4): 1545–8p.

Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. 2020; 117(17): 9490–6p.

Syal K. COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy. J. Med. Virol. 2020.

Zeng Q-L, Yu Z-J, Gou J-J, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J. Infect. Dis. 2020.

Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev. 2020; 16(3): 427–33p.

Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med. Drug Discov. 2020; 5: 100019p.

Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27(5): 1451–4p.

Kandasamy M. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19. Med. Drug Discov. 2020; 6: 100042p.

Atzrodt CL, Maknojia I, McCarthy RDP, et al. A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2. FEBS J. 2020.

Ghosh S, Firdous SM, Nath A. siRNA could be a potential therapy for covid-19. EXCLI J. 2020; 19: 528–31p.

Aanouz I, Belhassan A, El-Khatabi K, et al. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations. J. Biomol. Struct. Dyn. 2020;1–9p.

Du H-Z, Hou X-Y, Miao Y-H, et al. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Chin. J. Nat. Med. 2020; 18(3): 206–10p.

Balachandar V, Mahalaxmi I, Kaavya J, et al. COVID-19: Emerging Protective Measures. Eur. Rev. Med. Pharmacol. Sci. 2020; 24: 3422–5p.

Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. J. Biomol. Struct. Dyn. 2020; 1–10p.

Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020; 368(6489): 409–12p.

Abdelli I, Hassani F, Bekkel Brikci S, et al. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria. J. Biomol. Struct. Dyn. 2020; 1–14p.

Cherrak SA, Merzouk H, Mokhtari-Soulimane N. Potential Bioactive glycosylated flavonoids as SARS-CoV-2 Main protease Inhibitors: A molecular Docking Study. PLoS ONE. 2020; 15(10): e0240653.

Jacobs JJL. Neutralizing antibodies mediate virus-immune pathology of COVID-19. Med. Hypotheses. 2020; 143: 109884p.

Silberstein M. Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19? Med. Hypotheses. 2020; 140: 109767p.

Gurwitz D. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Drug Dev. Res. 2020.

Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020; 11(1): 1620p.

Wu S. Progress and Concept for COVID‐19 Vaccine Development. Biotechnol. J. 2020; 2000147p.

Verbeke R, Lentacker I, De Smedt SC, et al. The dawn of mRNA vaccines: The COVID-19 case. J. Control. Release. 2021; 333: 511–20p.

Mahase E. Covid-19: Oxford researchers halt vaccine trial while adverse reaction is investigated. Br. Med. .J. 2020; m3525.



  • There are currently no refbacks.